Vaccination against hepatitis B virus in Spain a cost-effectiveness analysis

Vaccine

Volumn 15, Issue 15, 1997, Pages 1652-1660

  Garuz, Roberto ^a,h   Torrea, José Luis ^b   Arnal, José María ^c   Forcen, Tarsicio ^d   Trinxet, Cristina ^e   Anton, Francisco ^f   Antoñanzas, Fernando ^g  

^a Primary Care Direction   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Actur Health Center   (Spain)

^d Tafalla Health Center   (Spain)

^e Catalonian Health Institute   (Spain)

^f HOSPITAL SAN PEDRO   (Spain)

^g UNIVERSITY OF LA RIOJA   (Spain)

^h NONE   (Spain)

Author keywords

Cost effectiveness; Hepatitis B; Vaccine

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; MATHEMATICAL MODEL; PASSIVE IMMUNIZATION; PREVALENCE; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SIMULATION; SPAIN; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HEPATITIS B VACCINES; HUMANS; INFANT; MIDDLE AGED; SPAIN; VACCINATION;

EID: 0030863064     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00083-2     Document Type: Article

References (39)

1. Bruguera, M. and Sánchez Tapias, J.M. Epidemiologie de la hepatitis B en España. Medicina Clinica (Barcelona) 1990, 95, 470-475.
2. Salleras, L., Bruguera, M. and Vidal, J. et al. Prevalence of hepatitis B markers in the population of Catalonia (Spain). Rationale for universal vaccination of adolescents. European Journal of Epidemiology 1992, 8, 640-644.
3. Encuesta sero epidemiológica de la Comunidad de Madrid. Instituto Carlos III. Insalud, Dirección Provincial de Madrid. Consejeria de Salud de la Comunidad Autónoma de Madrid. Ed. Servicio Regional de Salud, Madrid 1990.
4. Maynard, J.E., Kane, M.A. and Hadler, S.C. Global control of hepatitis B through vaccination: the role of hepatitis B vaccine in the Expanded Programme on Immunization. Review of Infectious Diseases 1989, 2, (Suppl 3), 574-578.
5. Mulley, A.G., Silverstein, M.D. and Dienstag, J.L. Indications for use of hepatitis B vaccine, based on cost effectiveness analysis. New England Journal of Medicine 1982, 307, 644-652.
6. Szmuness, W., Harley, E.J., Ikrarn, H. and Stevens, C.E. Sociodemographic aspects of the epidemiology of hepatitis B. In Viral hepatitis (Eds Vyas, G.N., Coen, S.N. and Schmid, R). Franklin Institute Press, Philadelphia, PA, 1978, pp. 297-320
7. André, F.E. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. American Journal of Medicine 1989, 87, 3A.14S-3A.20S.
8. Scheiermann, N., Gesemann, M., Maurer, C., Just, M. and Berger, R. Persistence of antibodies after immunization with a recombinant yeast derived hepatitis B vaccine following two different schedules. Vaccine 1990, 8, (Suppl), 44-45.
9. Campbell, A.D. et al. Efficacy of hepatitis B vaccine. Journal of the Society of Occupational Medicine 1988, 38, 46-47.
10. Lee, C.Y. et al. Low dose hepatitis B vaccine. Lancet 1989, 2, 860-861.
11. National Advisory Committee on Immunization (NACI) Statement on hepatitis B vaccine. Canadian Communicable Disease Report 1993, 19, 104-115.
12. Anonymous. Safety to hepatitis B vaccine confirmed. FDA Drug Bulletin 1988, 14-15.
13. Blumberg, B.S. International Conference on Prospects for Eradication of Hepatitis B virus. Vaccine 1990, 8, (Suppl.), 5.
14. Jönsson, B., Horisberg, B., Bruguera, M. and Matter, L. Cost benefit analysis of hepatitis B vaccination. A computerized decision model for Spain. International Journal of Technological Assessment of Health Care 1991, 7, 379-402.
15. Antoñanzas, F., Forcén, T. and Garuz, R. Análisis coste efectividad de la vacunación frente al virus de la hepatitis B. Medicina Clinica (Barcelona) 1992, 99, 41-46.
16. Antonanzas, F., Garuz, R., Rovira, J., Trixet, C., Navas, E. and Salleras, L. Cost effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. PharmacoEconomics 1995, 5, 428-443.
17. Garuz, R., Arnal, J.M., Forcen, T., Trinxet, C. and Antoñanzas, F. Análisis coste efectividad de la prevención prenatal frente al virus de la hepatitis B. Anales Espanoles de Pediatria 1994, 40, 405-410.
18. Rivera, F., Lissen, E. and Vazquez, R. et al. Análisis coste beneficio de un programa de vacunación contra la hepatitis B en personal sanitario hospitalario. Medicina Clinica (Barcelona) 1984, 83, 611-614.
19. Navas, E., Bayas, J.M., Taberner, J.L. and Salleras, L. Eficiencia de la detección prevacunal de anti HBc en los programas de vacunación antibepatitis B. Medicina Clinica (Barcelona) 1992, 99, 641-644.
20. Andrés, M., Lluch, J.A., Momparler, P. and Redondo, M.J. Evaluación de un programa de vacunación antihepatitis B en adolescentes. V Congreso de la Sociedad Espanola de Salud Pública y Administración Sanitaria (SESPAS), Granada, 1993.
21. André, F.E. and Safary, A. Summary of clinical findings on Engerix B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Medical Journal 1987, 63, (Suppl.2), 169-178.
22. National Advisory Committee on Immunization (NACI) Statement on hepatitis B vaccine. Canadian Communicable Disease Report 1993, 19, 104-115.
23. Doubilet, P. et al. Probabilistic sensitivity analysis using Montecarlo simulation. Medical Decision Making 1985, 5, 157-177.
24. Arévalo, J.A. and Washington, A.E. Cost effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988, 259, 365-369.
25. Stevens, C.E., Toy, P. and Tong, M.J. et al. Perinatal hepatitis B virus transmission in the Unites States: prevention by passive-active immunization. JAMA 1985, 253, 1740-1745.
26. Lok, A.S.F., Lai, C.L., Wu, P.C., Leung, E.K.Y. and Lam, T.S. Spontaneous hepatitis B antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987, 92, 1839-1843.
27. Alward, W.L.M., McMahon, B.J., Hall, D.B., Heyward, W.L., Francis, D.P. and Bender, T.R. The long term serological course of asyntomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. Journal of Infectious Disease 1985, 151, 604-609.
28. Viola, L.A., Barrison, I.C. and Coleman, J.C. et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Lancet 1981, II, 1156-1159.
29. Davis, G.L., Hoofnagle, J.H. and Waggoner, J.G. Spontaneous reactivation of chronic hepatitis B infection. Gastroenterology 1984, 86, 230-235.
30. Drummond, M.F., Stoddart, G.L. and Torrance, G.W. Análisis de coste. Metodos para la evaluación económica de los programas de atención de la salud. Ed. Diaz de Santos S.A., Madrid 1991, pp. 61-90.
31. Nokes, D.J. and Anderson, R.M. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes. Epidemiological Information 1988, 101, 1-20.
32. Torrea, J.L. and Garuz, R. Efectividad de la vacunación universal frente al virus de la hepatitis B. Simulación con un modelo matemático. Gaceta Sanit. 1994, 8, 294-303.
33. Bruguera, M., Sánchez, J.M. and Salleras, L. Catalonian programme to control hepatitis B. Working on the control of really hepatitis. Munich, 22-25 April 1991.
34. Roure, C. Cost benefit analysis: a decision making aid applied to immunization. Direction Generale de la Santé. Sous Direction de la Prévention Generale, Paris 1990. WHO, Regional Office for Europe.
35. Bloom, B.S., Hillman, A.L., Fendrick, A.M. and Schwartz, J.S. A reappraisal of hepatitis B virus vaccination strategies using cost effectiveness analysis. Annals of International Medicine 1993, 118, 298-306.
36. Goicoechea, M.J., Campos, A., Baranda, J., Sánchez, J.M. and Domínguez, C. Estudio seroepidemiológico de marcadores de hepatitis B en embarazadas de la provincia de Soria. II reunión de la SEIMC. Sevilla, 1987.
37. Poovorawiam, J., Sanpavat, S., Pongpunlert, W. and Chuhmermpadetsuk, S. et al. Comparision of recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immuneglobulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990, 8, (Suppl), 256-259.
38. Dealplane, D., Yogev, R. and Crussi, F. et al. Fatal hepatitis B in early infancy: The importance of identifying HbsAg positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics 1983, 72, 176-180.
39. Sinatra, F.R., Shah, P. and Weissman, J.Y. et al. Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen positive carrier mothers Pediatrics 1982, 70, 557-561.